- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | Attovia to present clinical data on IL-31 therapies at conferences | 3 | Investing.com | ||
| 28.09. | VM-Test BYD Atto 2: Vernunftwagen mit Kampfpreis und kurzer Leine | 38 | VISION mobility | ||
| 25.09. | VM-Test BYD Atto 2: Vernunftwagen zum Kampfpreis | 25 | VISION mobility | ||
| 18.09. | BYD Atto 2: China-Update bringt 501 km Reichweite | 17 | ElektroQuatsch | ||
| 16.09. | Attovia auf Morgan Stanley Konferenz: Pipeline-Fortschritte nach Börsengang | 1 | Investing.com Deutsch | ||
| ATTOVIA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | BYD's Most Powerful ATTO 3 Lands In Malaysia | 27 | BusinessToday | ||
| 02.09. | Attovia flags ATTO-1310 itch data, Phase 1b readout Q4 | 1 | The Market Online Canada | ||
| 02.09. | Attovia Therapeutics, Inc. GAAP EPS of -$4.88 misses by $4.25, revenue of $0.45M | 1 | Seeking Alpha | ||
| 02.09. | Attovia Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.09. | Attovia Therapeutics, Inc.: Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | 427 | GlobeNewswire (Europe) | ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of ATTO-1310 in chronic... ► Artikel lesen | |
| 31.08. | Attovia: Positive Studiendaten zu Juckreiz-Medikament beflügeln Analysten | 1 | Investing.com Deutsch | ||
| 31.08. | RBC startet Coverage für Attovia mit "Outperform" und sieht über 115 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 31.08. | RBC initiates Attovia stock with Outperform on IL-31 drug potential | 1 | Investing.com | ||
| 31.08. | Morgan Stanley startet Coverage für Attovia mit "Overweight" | 1 | Investing.com Deutsch | ||
| 31.08. | Morgan Stanley initiates Attovia stock with overweight rating | 1 | Investing.com | ||
| 16.08. | BYD Atto 3 Evo im Test: Viel Auto für den Preis | 4.328 | electrive.net | Von außen ändert sich fast nichts, unter dem Blech aber praktisch alles: BYD hat beim Atto 3 Evo genau die beiden Schwächen behoben, die den Vorgänger ausgebremst haben. Statt mit nur 110 kW lädt er... ► Artikel lesen | |
| 06.08. | Attovia Therapeutics, Inc.: Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 419 | GlobeNewswire (Europe) | SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia") (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for... ► Artikel lesen | |
| 06.08. | Qiming Venture Partners: Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq | 533 | PR Newswire | SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq... ► Artikel lesen | |
| 05.08. | Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders | 2 | MedCity News | ||
| 05.08. | Attovia adds to biotech IPO momentum with $289M offering | 1 | BioPharma Dive |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,768 | -1,35 % | Aufgepasst! Den nächsten Kurstreiber früh erkennen, diese Meilensteine könnten die Bewertung von Lahontan Gold, Evotec und Deutz bald verändern! | Zuschlagen, bevor die Aktie anspringt! Dabei ist entscheidend, den Auslöser für den nächsten Kursimpuls früh genug zu erkennen. Lahontan Gold arbeitet an der Inbetriebnahme einer historischen Goldmine... ► Artikel lesen | |
| ABIVAX | 79,00 | +2,86 % | Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization | ||
| LAKEFRONT BIOTHERAPEUTICS | 26,360 | +2,33 % | Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America | Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Pursuant... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,450 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,960 | 0,00 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| CYTOKINETICS | 53,94 | -3,99 % | Cytokinetics, Incorporated: Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program | Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen | |
| FAETH THERAPEUTICS | 22,400 | +2,75 % | Citizens bekräftigt Rating für Faeth Therapeutics angesichts Studie zu Endometriumkarzinom | ||
| CYTOMX THERAPEUTICS | 2,236 | -2,36 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 3,950 | -3,28 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder | Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022)
60% of HETLIOZ® treated participants shifted sleep... ► Artikel lesen | |
| BIOAGE LABS | 5,675 | +0,18 % | BioAge Labs-Aktie mit -77% - jetzt zuschlagen? | Die BioAge-Labs-Aktie ist seit ihrem Hoch im Juli dramatisch eingebrochen und notiert aktuell nur noch bei 6,29 US$. Der jüngste Abverkauf hat nun die im Chart markierte Kurslücke vollständig geschlossen.... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,009 | -6,23 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update | Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved... ► Artikel lesen | |
| FORTRESS BIOTECH | 2,140 | +0,23 % | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | ZYCUBO approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,770 | -1,49 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| SERES THERAPEUTICS | 2,410 | 0,00 % | Seres Therapeutics, Inc.: Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 | Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST net sales-based milestones Restructured lease materially reduces ongoing annual... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,980 | -0,33 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen |
ATTOVIA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 16,130 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATTOVIA THERAPEUTICS INC finden Sie auf Wallstreet Online.